Compare HUBB & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBB | PODD |
|---|---|---|
| Founded | 1888 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2B | 22.1B |
| IPO Year | N/A | 2007 |
| Metric | HUBB | PODD |
|---|---|---|
| Price | $439.93 | $304.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 19 |
| Target Price | ★ $474.00 | $359.00 |
| AVG Volume (30 Days) | 464.2K | ★ 765.6K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | ★ 15.10 | N/A |
| EPS | ★ 15.99 | 3.45 |
| Revenue | ★ $5,686,200,000.00 | $2,521,800,000.00 |
| Revenue This Year | $5.89 | $32.55 |
| Revenue Next Year | $7.65 | $20.39 |
| P/E Ratio | ★ $27.55 | $88.24 |
| Revenue Growth | 0.82 | ★ 27.11 |
| 52 Week Low | $299.43 | $230.05 |
| 52 Week High | $484.26 | $354.88 |
| Indicator | HUBB | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 54.20 | 40.94 |
| Support Level | $422.10 | $303.20 |
| Resistance Level | $432.90 | $317.34 |
| Average True Range (ATR) | 11.19 | 13.12 |
| MACD | 1.16 | -2.82 |
| Stochastic Oscillator | 92.59 | 3.14 |
Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, electrical substations, and within commercial and industrial buildings. The company's primary operations are within the United States, where around 90% of revenue is derived.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.